We wrote earlier about Algorithmiq and its partnership with IBM. Algorithmiq’s ambition is to use quantum computing to bring efficiencies to drug discovery and carve out a break out market space around Quantum Biotech.
Please see below for a fascinating exchange with Sabrina Maniscalo and Algorithmiq’s path to solving an important problem using quantum computing.
What’s your background? How did you end up becoming an entrepreneur?
I am Sabrina Maniscalco, a Sicilian living in Finland, and I’m a professor of quantum information, computing, and logic at the University of Helsinki. I’m also the CEO and co- founder of Algorithmiq. I’ve been working in quantum science and technology for over 20 years.
My expertise lies in the very subtle interactions that quantum systems have with everything around them. There is a very technical term called open quantum systems, and there’s a theory that describes them. It is really about why quantum systems are so fragile and delicate, which is the reason why we have errors in today’s quantum computers. It is one of the main enemies of existing devices because we want to make them as perfect as possible in order to really operate at a large scale.
It was the right opportunity to start Algorithmiq as I had assembled an amazing team and we saw the opportunity to commercialize our IP after a fruitful scientific collaboration with the team of quantum physicists of IBM Zurich.
What problem are you trying to solve at Algorithmiq with quantum computing? How is joining IBM Quantum Network an advantage for Algorithmiq?
We are focused on leveraging the power of quantum computing so that new drugs can be explored and eventually brought to market, and cost-effectively, leading to precise medical treatments. On average, it currently takes around a decade and $1 billion for a new drug to get to market. ...
READ MORE |